Prediction of adverse effects in patients with benign prostatic hyperplasia treated with 5 alpha reductase inhibitors

Sofronievska, Maja and Jovevska, Svetlana (2019) Prediction of adverse effects in patients with benign prostatic hyperplasia treated with 5 alpha reductase inhibitors. In: 1st Balkan Congress of Urology, 05-07 Apr 2019, Ohrid.

	Text Programa_Prediction_of_adverse_effects.pdf Download (2MB)
	Text Abstract_Prediction_of_adverse_effects.pdf Download (1MB)
	Text PREDICTION_OF_ADVERSE_EFFECTS_IN_PATIENTS_WITH_BEN.pdf Download (807kB)

Abstract

Five alfa reductase inhibitors (5ARI) are widely used for treatment of benign prostatic hyperplasia (BPH) as they have a positive impact on the reduction of prostate volume and PSA levels, but also lead to adverse effects: erectile dysfunction, depressed mood and gynecomastia, which make the post 5ARI syndrome. The basis of its occurrence is the inhibition of 5 alpha reductases and blocking the biosynthesis of powerful neurosteroids from their precursor dehydroepiandrosterone and the conversion of testosterone to dihydrotestosterone. The aim of this paper is to show the significance and role of the dehydroepiandrosterone in patients with BPH who are on 5ARI therapy as an important predictor of post-5ARI syndrome. We made a comparative prospective analysis of 222 patients with BPH, of which 110 belong to the control group and were treated with alpha blocker (tamsulosin) and the remaining 112 patients were on combination therapy, alpha blocker and 5 ARI (dutasteride). In both groups of patients in the interval of 6 months over a year, the symptoms of lower urinary tract, erectile function index, and Beck depression index were analyzed with simultaneous monitoring of serum levels of testosterone and dehydroepiandrosterone. We concluded that post-5ARI syndrome, erectile dysfunction, and mood disorders appeared in 20 patients (19%) of the 5-ARI group, while no control group patients showed any such disorders in the control group. They were in correlation (r=89) with initially low levels of dehydroepiandrosterone and testosterone in patients with BPH before initiation of therapy.
Keywords: BPH, erectile dysfunction, depression, dehidroepiandrosterone

Item Type:	Conference or Workshop Item (Poster)
Subjects:	Medical and Health Sciences > Clinical medicine Medical and Health Sciences > Health sciences
Divisions:	Faculty of Medical Science
Depositing User:	Maja Sofronievska
Date Deposited:	01 Nov 2022 08:38
Last Modified:	01 Nov 2022 08:38
URI:	https://eprints.ugd.edu.mk/id/eprint/29980

Actions (login required)

View Item